ARTICLE | Discovery & Translation
BioCentury’s roundup of translational innovations
By Danielle Golovin, Senior Biopharma Analyst
May 29, 2024 11:58 PM UTC


Cimeio Therapeutics Inc., ADC Therapeutics S.A. (NYSE:ADCT) and collaborators at University of Basel selectively eradicated leukemic cells while preserving hematopoiesis by shielding healthy cells from an ADC targeting a pan-hematopoietic marker.
The Nature paper authors engineered a base edit in PTPRC that preserved hematopoietic stem and progenitor cell (HSPC) functions but shielded them from a PTPRC-targeting antibody-drug conjugate. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652511/science-spotlight-cimeio-s-cell-shielding-technology-stopping-ebv-driven-cancer-and-more